SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Jul 9, 2020

Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: July 9, 2020 · CIK: 0001213037 · Accession: 0001104659-20-082329

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-239464

Date

July 9, 2020

Author

Not clearly detected

Form

CORRESP

Company

Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)

Letter

Cardiff Oncology, Inc.

Flintkote Avenue

San Diego, CA 92121

July 9, 2020

VIA EDGAR

United States Securities

and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Abby Adams

Re: Cardiff Oncology, Inc.

Form S-1

File No. 333-239464

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Cardiff Oncology, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Friday, July 10, 2020, or as soon thereafter as possible.

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

Thank you,

CARDIFF ONCOLOGY, INC.

By: /s/ Mark Erlander

Name: Mark Erlander

Title: Chief Executive Officer

-1-

Show Raw Text

CORRESP
1
filename1.htm

Cardiff
Oncology, Inc.

11055
Flintkote Avenue

San Diego,
CA 92121

July
9, 2020

VIA
EDGAR

United States
Securities

and Exchange Commission

100 F Street,
N.E.

Washington,
D.C. 20549

Attention:
Abby Adams

    Re:
    Cardiff Oncology, Inc.

    Form S-1

    File No. 333-239464

Ladies and
Gentlemen:

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Cardiff
Oncology, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred
to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Friday, July 10, 2020, or as
soon thereafter as possible.

Please
notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon
as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

    Thank you,

    CARDIFF ONCOLOGY, INC.

    By:
    /s/
Mark Erlander

    Name: Mark Erlander

    Title: Chief Executive Officer

    -1-

SecProbe.io